Verily Health Raises $300M as Alphabet Cedes Control

Series X Capital leads the round; Alphabet steps back to a minority stake as Verily restructures as an independent corporation targeting enterprise precision health.

Verily Health secured $300 million in funding on March 19, with Series X Capital leading the round and Alphabet, UCHealth, and the University of Colorado Anschutz participating. The investment ends Alphabet’s controlling stake in the health AI company, reducing Google’s parent to a significant minority investor. 

Alongside the funding, Verily converted its legal structure from a limited liability company to a corporation and adopted the official name Verily Health Inc. The company said it plans to use the capital to accelerate its AI-native precision health platform, which helps enterprise customers consolidate healthcare data and deploy it in research and clinical workflows. 

From research to care, our customers need solutions that bring the best of clinical and scientific rigor together with AI to deliver the next generation of healthcare.
Stephen Gillett, Chairman & CEO, Verily

Verily first emerged from Google X approximately 10 years ago as one of Alphabet’s earliest Other Bets. Series X Capital, the venture fund established in collaboration with Google’s X division to commercialize moonshot projects, will now lead the company’s next phase. Gideon Yu, Founder and Managing Partner of Series X Capital, described the round as a milestone for Verily’s commercial momentum in precision health. 

Alphabet President and Chief Investment Officer Ruth Porat said that bringing in new investors alongside Alphabet’s continued participation positions Verily to improve patient outcomes and lower the cost of healthcare delivery. The statement did not disclose the value of Alphabet’s remaining stake or the company’s post-round valuation. 

ALSO READ: Kleiner Perkins Leads $6M Seed Round in Health Universe

The restructuring has direct implications for Verily’s enterprise business. As a subsidiary of an Alphabet-controlled entity, Verily faced questions from prospective healthcare partners about data governance and competitive neutrality. Operating as an independent corporation under minority Alphabet ownership removes that structural complication, though it is unclear whether existing or pending contracts were contingent on the change.

Verily has closed several commercial agreements in recent months. The company announced a collaboration with Samsung’s Galaxy Watch to support biomarker development on its Pre platform for life sciences customers, and a separate integration with Salesforce that connects the Verily Pre Platform with Agentforce Health for enterprise precision health workflows. UCHealth and the University of Colorado Anschutz are also using the Pre platform for AI-powered research and care delivery. 

The move comes as enterprise health AI spending continues to grow among hospital systems, payers, and life sciences firms seeking to operationalize large clinical datasets. Verily’s two principal offerings are the Pre platform, which organizes fragmented health records, genomic data, and wearable inputs for AI analysis, and Lightpath, a care management platform for patients with chronic conditions, including diabetes.

Verily Health is headquartered in Dallas, Texas, and operates at the intersection of data science, technology, and healthcare delivery. 

Disclaimer: This article is based on a publicly available press release from Verily Health. Nervnow has not independently verified any of the claims.

MORE ON STARTUPS & FUNDING:
Oasis Security Raises $120 Million to Govern AI Agent Access
Surf AI Raises $57M Series A to Scale AI Security Platform 
Agnes AI Raises Tens of Millions in Funding
One-Year-Old Wonderful Raises $150M in New Funding
DiligenceSquared Raises $5M to Let AI Do What McKinsey Charges $1M For